Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer

NCT01732783 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01732783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01732783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
December 10, 2012
Completion date
November 30, 2016
Enrollment
213 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

wild-type ras metastatic colorectal cancer